Amneal Pharmaceuticals (AMRX) Revenue (2017 - 2025)
Historic Revenue for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $784.5 million.
- Amneal Pharmaceuticals' Revenue rose 1167.95% to $784.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 949.62%. This contributed to the annual value of $2.8 billion for FY2024, which is 1672.58% up from last year.
- Amneal Pharmaceuticals' Revenue amounted to $784.5 million in Q3 2025, which was up 1167.95% from $724.5 million recorded in Q2 2025.
- In the past 5 years, Amneal Pharmaceuticals' Revenue registered a high of $784.5 million during Q3 2025, and its lowest value of $493.1 million during Q1 2021.
- Its 5-year average for Revenue is $615.7 million, with a median of $609.8 million in 2022.
- Its Revenue has fluctuated over the past 5 years, first crashed by 108.88% in 2021, then skyrocketed by 1840.2% in 2024.
- Amneal Pharmaceuticals' Revenue (Quarter) stood at $536.9 million in 2021, then grew by 13.57% to $609.8 million in 2022, then rose by 1.18% to $617.0 million in 2023, then rose by 18.4% to $730.5 million in 2024, then grew by 7.39% to $784.5 million in 2025.
- Its Revenue was $784.5 million in Q3 2025, compared to $724.5 million in Q2 2025 and $695.4 million in Q1 2025.